All Stories

  1. The Ketogenic Diet in the Prevention and Treatment of Hypertension (HTN)
  2. Screening and Treatment Intervention for Insulin Resistance/Hyperinsulinemia in the General Population to Prevent Heart Failure or Slow Its Worsening
  3. Taking Into Account Insulin Resistance With Associated Hyperinsulinemia to Counteract the Development of Acute and Chronic Cardiovascular Diseases
  4. Indomethacin, a drug with known antiviral activity against SARS-CoVs neglected during the COVID-19 pandemic
  5. Cardiovascular Diseases: From Pathophysiology to Novel Therapeutic Approaches
  6. Association of insulin and GH/IGF-1 derangements and heart failure: a narrative review
  7. Prevalence of TyG-Defined Insulin Resistance and Its Association With Recorded Cardiovascular Disease Among Adults in the Municipality of Naples: A Retrospective Cross-Sectional Primary-Care Study
  8. Insulin Resistance/Hyperinsulinemia Should Be Considered in the Prevention and Treatment of Essential Hypertension
  9. Feature Reviews in Cardiovascular Diseases
  10. Aging of the vascular system: proposal of preventive intervention with known natural substances
  11. COVID-19 vaccinations in adults and evaluation of cardiovascular events: critical methodological issues
  12. Insulin Resistance with Associated Hyperinsulinemia as a Cause of the Development and Worsening of Heart Failure
  13. Autoantibodies Targeting G-Protein-Coupled Receptors and RAS-Related Molecules in Post-Acute COVID Vaccination Syndrome: A Retrospective Case Series Study
  14. Chronically Increased Levels of Circulating Insulin Secondary to Insulin Resistance: A Silent Killer
  15. Insulin Resistance, a Risk Factor for Alzheimer’s Disease: Pathological Mechanisms and a New Proposal for a Preventive Therapeutic Approach
  16. Insulin Resistance/Hyperinsulinemia as an Independent Risk Factor That Has Been Overlooked for Too Long
  17. Insulin Resistance/Hyperinsulinemia, Neglected Risk Factor for the Development and Worsening of Heart Failure with Preserved Ejection Fraction
  18. Insulin resistance/hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated
  19. A case of adverse reaction to booster dose of COVID-19 vaccination: could D-dimer elevation suggest increased clotting risk?
  20. The Negative Impact of Insulin Resistance/Hyperinsulinemia on Chronic Heart Failure and the Potential Benefits of Its Screening and Treatment
  21. Editorial: Methods in general cardiovascular medicine
  22. A Descriptive Review of the Action Mechanisms of Berberine, Quercetin and Silymarin on Insulin Resistance/Hyperinsulinemia and Cardiovascular Prevention
  23. Early Multi-Target Treatment of Mild-to-Moderate COVID-19, Particularly in Terms of Non-Steroidal Anti-Inflammatory Drugs and Indomethacin
  24. COVID-19 Medical and Pharmacological Management in the European Countries Compared to Italy: An Overview
  25. A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Management of Mild-to-Moderate Symptomatic COVID-19
  26. Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis of Early COVID-19 and Treated at Home Within 3 Days or After 3 Days of Symptom Onset with Prescribed and Non-Prescribed Treatments Between Novembe...
  27. Home pharmacological therapy in early COVID‐19 to prevent hospitalization and reduce mortality: Time for a suitable proposal
  28. Sustained High D-Dimer in Outpatients Who Have Recovered from Mild to Moderate Coronavirus Disease 2019 (COVID-19)
  29. COVID-19: Off-label therapies based on mechanism of action while waiting for evidence-based medicine recommendations
  30. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial
  31. Efficacy of sildenafil in HIV-related pulmonary arterial hypertension
  32. Response to letter by Wang Q et al. regarding article “Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension”
  33. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension
  34. Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: Case report and review of the literature
  35. Effects of a nutraceutical combination on left ventricular remodeling and vasoreactivity in subjects with the metabolic syndrome
  36. Reply:
  37. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome
  38. Insulin resistance: Is it time for primary prevention?
  39. The Importance of Tricuspid Regurgitation and Right Ventricular Overload in ICD/CRT Recipients: Beside the Left, beyond the Left
  40. Endocrine Alterations Are the Main Determinants of Cardiac Remodelling in Restrictive Anorexia Nervosa
  41. Cardiac involvement in active uncomplicated acromegaly
  42. A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
  43. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study
  44. Letter by Fazio and Carlomagno Regarding Article, “Heart Rate Predicts Outcomes in an Implantable Cardioverter-Defibrillator Population”
  45. Thyroid Hormones and Cardiovascular System: From Bench to Bedside
  46. Late Onset of Hypoxemia Due to a Pulmonary Arteriovenous Malformation During Selective Estrogen Receptor Modulator Therapy
  47. Cardiovascular and metabolic effects of Berberine
  48. Efficacy and safety of valsartan plus hydroclorothiazide for high blood pressure
  49. Long term combination treatment for severe idiopathic pulmonary arterial hypertension
  50. Usefulness of NT-proBNP in the assessment of patients with aortic or mitral regurgitation
  51. Growth Hormone Deficiency in Patients with Chronic Heart Failure and Beneficial Effects of Its Correction
  52. The GH/IGF-1 Axis and Heart Failure
  53. Myocarditis and dilated cardiomyopathy: possible connections and treatments
  54. Effects of Growth Hormone on Exercise Capacity and Cardiopulmonary Performance in Patients with Chronic Heart Failure
  55. Prehypertension and Elevated Risk of Cardiovascular Disease: Physiopathologic Mechanisms
  56. Association between post-ischemic forearm blood flow and blood pressure response to maximal exercise in well trained healthy young men
  57. Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension
  58. Aerobic exercise performance correlates with post-ischemic flow-mediated dilation of the brachial artery in young healthy men
  59. Tadalafil in Primary Pulmonary Arterial Hypertension
  60. Long-term efficacy of doxazosin plus atenolol in the management of severe and sustained arterial hypertension and reversibility of the cardiac damage induced by chronic cathecolamine excess. A case report in a young girl with recurrent, functioning par...
  61. Myocardial contractility and total arterial stiffness in patients with overt hyperthyroidism: acute effects of beta1-adrenergic blockade
  62. Peak exercise oxygen uptake and left ventricular systolic and diastolic function and arterial mechanics in healthy young men
  63. Effects of Thyroid Hormone on the Cardiovascular System
  64. Hyperthyroidism, Subclinical
  65. Subclinical Hypothyroidism and Cardiovascular Risk
  66. Subclinical Thyroid Dysfunction and the Heart
  67. Reactive hyperemia and cardiovascular performance in athletes regularly trained
  68. Prospective Evaluation of Hypertensive Patients with Carotid Kinking and Coiling: An Ultrasonographic 7-Year Study
  69. Cardiovascular Safety of Acute Recombinant Human Thyrotropin Administration to Patients Monitored for Differentiated Thyroid Cancer
  70. The importance of using strict inclusion criteria in subclinical hypothyroid studies
  71. Effects of Subclinical Thyroid Dysfunction on the Heart
  72. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study
  73. Patients with Subclinical Cushing’s Syndrome due to Adrenal Adenoma Have Increased Cardiovascular Risk
  74. Subclinical Hypothyroidism and Cardiac Function
  75. Supraphysiological Doses of GH Induce Rapid Changes in Cardiac Morphology and Function
  76. Supraphysiological Doses of GH Induce Rapid Changes in Cardiac Morphology and Function
  77. Aldosterone Receptor Blockade in the Management of Heart Failure
  78. Effects of Thyroid Hormone on Cardiac Function - The Relative Importance of Heart Rate, Loading Conditions, and Myocardial Contractility in the Regulation of Cardiac Performance in Human Hyperthyroidism
  79. Effects of Thyroid Hormone on Cardiac Function - The Relative Importance of Heart Rate, Loading Conditions, and Myocardial Contractility in the Regulation of Cardiac Performance in Human Hyperthyroidism
  80. Mortality in elderly patients with subclinical hyperthyroidism
  81. Mortality in elderly patients with subclinical hyperthyroidism
  82. Growth hormone corrects vascular dysfunction in patients with chronic heart failure
  83. Impact of Hyperthyroidism and Its Correction on Vascular Reactivity in Humans
  84. Does the Growth Factor Approach Have a Future in the Treatment of Human Heart failure?
  85. Endogenous Subclinical Hyperthyroidism Affects Quality of Life and Cardiac Morphology and Function in Young and Middle-Aged Patients*
  86. Endogenous Subclinical Hyperthyroidism Affects Quality of Life and Cardiac Morphology and Function in Young and Middle-Aged Patients
  87. Growth hormone and cardiac function
  88. The role of the GH-IGF-I axis in the regulation of myocardial growth: from experimental models to human evidence
  89. Cardiovascular Effects of Short-Term Growth Hormone Hypersecretion
  90. Cardiovascular Effects of Short-Term Growth Hormone Hypersecretion
  91. Heart Failure: Potential Benefit of Growth Hormone Therapy
  92. A Direct Role for the Macrophage Low Density Lipoprotein Receptor in Atherosclerotic Lesion Formation
  93. Left Ventricular Diastolic Dysfunction in Patients with Subclinical Hypothyroidism
  94. Left Ventricular Diastolic Dysfunction in Patients with Subclinical Hypothyroidism
  95. Growth Hormone and the Heart
  96. Growth hormone as a potential future therapy for congestive heart failure
  97. Growth Hormone in Heart Failure
  98. Cardiac Effects of Growth Hormone in Physiology and in Heart Failure
  99. Doxorubicin‐induced cardiomyopathy treated with carvedilol
  100. Reentrant Atrioventricular Nodal Tachycardia Induced by Levothyroxine
  101. Sympathetic deactivation by growth hormone treatment in patients with dilated cardiomyopathy
  102. Increased Arterial Intima-Media Thickness in Childhood-Onset Growth Hormone Deficiency
  103. Increased Arterial Intima-Media Thickness in Childhood-Onset Growth Hormone Deficiency
  104. Growth hormone and heart performance: A novel mechanism of cardiac wall stress regulation in humans
  105. Prevalence of Carotid Kinking and Coiling in a Population at Risk
  106. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine
  107. Growth Hormone in the Treatment of Dilated Cardiomyopathy
  108. Cardiovascular aspects in acromegaly: Effects of treatment
  109. Improved left ventricular function after growth hormone replacement in patients with hypopituitarism: Assessment with radionuclide angiography
  110. A Preliminary Study of Growth Hormone in the Treatment of Dilated Cardiomyopathy
  111. Long-term growth hormone deficiency as a cause of cardiomyopathy and its reversibility with specific replacement therapy.
  112. Long-term growth hormone deficiency as a cause of cardiomyopathy and its reversibility with specific replacement therapy
  113. Cardiac performance: Growth hormone enters the race
  114. Impairment of lung volumes and respiratory muscle strength in adult patients with growth hormone deficiency
  115. Optimal determination of right ventricular filling dynamics in systemic hypertension
  116. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta- blockade
  117. Pacemaker Malfunction Due to Subcutaneous Emphysema
  118. Growth Hormone and the Heart
  119. Growth hormone and the heart
  120. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement
  121. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly
  122. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine
  123. Cardiac Effects of Long Term Thyrotropin-Suppressive Therapy with Levothyroxine
  124. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses
  125. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency
  126. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly
  127. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine
  128. Platelet Aggregability in Patients with a VVI Pacemaker
  129. Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study
  130. Capillary Blood Flow to the Skin of Forearm in Cirrhosis
  131. Influence of atenolol on the relationship between heart rate and qt interval in patients with exercise‐induced myocardial ischemia
  132. Pacemaker Malfunction Due to Subcutaneous Emphysema — A Case Report
  133. Evaluation, by Noninvasive Methods, of the Effects of Acute Loss of Thyroid Hormones on the Heart
  134. Follow‐Up of a Respiratory Rate Modulated Pacemaker
  135. Fourier Analysis in Patients with Different Pacing Modes
  136. Efficacy of Ticlopidine in the Prevention of Thromboembolic Events in Patients with VVI Pacemakers
  137. Cardiac function and sympathetic activity in young diabetics
  138. Cardiac function and sympathetic activity in young diabetics
  139. A prospective randomized trial of doxorubicinversus idarubicin in the treatment of advanced breast cancer
  140. Atenolol and Amiodarone: A Comparative Study of Their Anti-Ischaemic Effect
  141. Bisoprolol in the treatment of angina pectoris: a double blind comparison with verapamil
  142. Indapamide and atenolol in the treatment of hypertension: double-blind comparative and combination study
  143. Obesity and cardiac function.